Immunohistochemistry Stains

The ARUP Immunohistochemistry Laboratory performs more than 175 stains on formalin-fixed, paraffin-embedded tissues/cellblocks. These stains are used to detect the presence, abundance, and localization of specific proteins to aid in determining the direction of differentiation in neoplasms with similar morphology as well as to provide prognostic or therapeutic information, among other applications.

This lab is pathologist oriented, providing a stain and return service only, without interpretation, to our client pathologists to assist in their diagnostic studies. Most stains are returned the next day. The available stains are listed under the Stain and Return Immunohistochemistry tab. If interpretation is needed, please order a consultation.

To order a surgical pathology consultation, please use test code 2013263 Consultation, Surgical Pathology or 2013258 Consultation, Hematopathology. For more information, call (801)581-2507. Please include pertinent clinical history and surgical pathology report.

The Immunohistochemistry Laboratory has a menu of immunohistochemistry tests for which we will provide interpretation by one of our ARUP faculty pathologists. A list of these tests can be found under the Immunohistochemistry Tests tab. The ARUP Immunohistochemistry Laboratory is an NSABP-approved laboratory for the testing of breast markers.
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Test # Test Name Test Keywords Test Description
2003472 Breast 2 (GCDFP-15) by Immunohistochemistry Tumor Markers, Mammary carcinoma, Extramammary Pagets disease
  • Gross cystic disease fluid protein-15
  • Produced by cells with apocrine function
  • Differentiation marker for mammary carcinomas
  • Extramammary Paget disease
2003478 Cancer Antigen 125 by Immunohistochemistry Ovarian Cancer, Tumor Markers, Pleura, lung cancer
  • High molecular weight glycoprotein
  • Expressed by normal epithelial cells of the pleura, pericardium, peritoneum, fallopian tube, endometrium, and endocervix
  • Aids in identifying non-mucinous epithelial ovarian carcinomas, serous and endometrioid adenocarcinomas, Krukenberg tumors, and uterine myomas
2003869 E-Cadherin by Immunohistochemistry Mesothelioma, Breast Cancer, Tumor Markers Cellular adhesion molecule:
  • Loss associated with invasive carcinoma
  • Differentiates LCIS from DCIS in indeterminate breast carcinoma
  • Reduced expression in invasive bladder cancer and ductal carcinoma
  • No expression in lobular carcinoma and LCIS
2007332 ERBB2 (HER2)(HercepTest) by Immunohistochemistry HERCEP IHC
  • Predicts a patient’s response to Herceptin Therapy
See Test Code 0049174 for HercepTest with Interpretation.
2004516 Estrogen Receptor (ER) by Immunohistochemistry Ovarian Cancer, Breast Cancer, Tumor Markers Estrogen receptor-alpha:
  • Prognostic for breast cancer
  • Predictive for response of breast cancers to hormonal therapy
  • Differentiates endocervical from endometrial adenocarcinomas
2003969 Inhibin by Immunohistochemistry Brain Tumors, Ovarian Cancer
  • Expressed in Sertoli cells, granulosa cells, and prostate, brain, and adrenal cells
  • Present in sex-cord stromal tumors (including Sertoli cell tumors), adrenocortical tumors, placental and gestational trophoblastic lesions, granular cell tumors of gallbladder and extrahepatic bile ducts, and some carcinomas
2010787 PAX8 by Immunohistochemistry
  • Expressed in a high percentage of ovarian serous, endometroid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas
  • Important marker of ovarian cancer and a useful marker for the differential diagnosis in lung and neck tumors, or tumors at distant sites where primary lung carcinoma, breast carcinoma, or thyroid carcinoma are possibilities.
2004525 Progesterone Receptor (PR) by Immunohistochemistry Tumor Markers, Breast Cancer, Ovarian Cancer
  • Identifies A and B forms of progesterone
  • Predictive of response to hormone therapy for breast carcinoma and endometrial cancer
  • Aids in differentiating endocervical from endometrial adenocarcinomas